Concepedia

R. Xinyu

RX

Statistics

Publications

13

Citations

567

H-Index

11

Active since

2020

Affiliations

Texas A&M University(Current)

Lawrence Berkeley National Laboratory

Sorrento Therapeutics (United States)

The University of Texas Medical Branch at Galveston

R. Xinyu is an author at Texas A&M University specializing in drug discovery, medicinal chemistry, and enzyme inhibition.

ORCID

Publications per year

2020–2024

13

Publications

13

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

Kai S. Yang, R. Xinyu, Yuying Ma et al. · ChemMedChem · 2020 · 133 citations · Full text

, , +17

MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L**

R. Xinyu, Yugendar R. Alugubelli, Yuying Ma et al. · ChemMedChem · 2021 · 73 citations · Full text

, , +14

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease

Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua et al. · Journal of Medicinal Chemistry · 2024 · 72 citations · Full text

, , +15

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Wenyue Cao, Chia-Chuan Dean Cho, Zhi Geng et al. · ACS Central Science · 2022 · 56 citations · Full text

, , +15

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

Yugendar R. Alugubelli, Zhi Geng, Kai S. Yang et al. · European Journal of Medicinal Chemistry · 2022 · 52 citations · Full text

, , +16

1–5 of 13